NewAmsterdam Pharma Co. NV (NAMS)
27.34
+0.49
(+1.82%)
USD |
NASDAQ |
Aug 25, 16:00
27.25
-0.09
(-0.33%)
After-Hours: 05:43
NewAmsterdam Pharma Shareholders Equity (Quarterly) : 631.42M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 631.42M |
| March 31, 2026 | 665.22M |
| December 31, 2025 | 683.43M |
| September 30, 2025 | 728.07M |
| June 30, 2025 | 778.50M |
| March 31, 2025 | 777.36M |
| December 31, 2024 | 757.50M |
| September 30, 2024 | 378.86M |
| June 30, 2024 | 387.44M |
| Date | Value |
|---|---|
| March 31, 2024 | 411.80M |
| September 30, 2022 | 127.07M |
| June 30, 2022 | 131.85M |
| March 31, 2022 | 133.03M |
| December 31, 2021 | 131.64M |
| September 30, 2021 | 130.71M |
| June 30, 2021 | 128.98M |
| March 31, 2021 | 130.28M |
| December 31, 2020 | 127.46M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ProQR Therapeutics NV | 90.87M |
| Pharming Group NV | 257.03M |
| argenx SE | -- |
| Arcutis Biotherapeutics, Inc. | 220.58M |
| Damora Therapeutics, Inc. | 516.06M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 704.45M |
| Total Liabilities (Quarterly) | 73.03M |
| Debt to Equity Ratio | 0.0001 |
| Current Ratio | 9.034 |
| Net Debt Paydown Yield | 0.00% |